STE is the ticker symbol for STERIS plc, a publicly traded Healthcare sector company listed on NYSE. 13F Pro tracks STE with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is STE a good stock to buy?

13F Pro's AI ranking engine scores STE at 68.2/100, ranked #326 of 2,961 stocks based on 32 fundamental signals including profitability, growth, balance sheet strength, and free cash flow. The full AI verdict and bull/bear case for STE is available at https://13fpro.ai/company/STE. Not investment advice — review the underlying SEC filings before making any trade.

Where does 13F Pro source STE data?

All STERIS plc fundamentals and ownership data come directly from SEC EDGAR. STERIS plc files with the SEC under CIK 1757898. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

STERIS plc(STE)— Stock Profile, AI Score & Financials

Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

STERIS plc (STE) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores STE at 68.2/100 on a 32-signal composite quality model, placing it at rank #326 of 2,961 stocks — the top 25% of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), STERIS plc reports quarterly revenue of $1.5B, net income of $200.1M, an operating margin of 19.1%. Top institutional holders of STE by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. STE trades on the NYSE exchange and files with the SEC under CIK 1757898. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate STE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for STERIS plc directly from SEC EDGAR.

AI Quality Score

68.2/100

AI Rank

#326

Revenue

$1.5B

Net Income

$200.1M

Free Cash Flow

$279.6M

Operating Margin

19.1%

STE key financials by period

STERIS plc reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2026	10-K	$5.9B	$782.3M	18.6%
FY 2025	10-K	$5.5B	$614.6M	15.9%
FY 2024	10-K	$5.1B	$378.2M	16.3%
FY 2023	10-K	$4.5B	$107.0M	17.4%
FY 2022	10-K	$4.2B	$243.9M	11.3%
FY 2021	10-K	$3.1B	$397.4M	17.6%

Institutions holding STE

Institutional investors reporting a position in STERIS plc on SEC Form 13F.
Institution	Shares	Value	Reported
BlackRock	8,820,889	$1.9B	2026-06-30
VANGUARD CAPITAL MANAGEMENT	6,406,906	$1.3B	2026-06-30
STATE STREET	5,072,818	$1.1B	2026-06-30
VANGUARD PORTFOLIO MANAGEMENT	5,001,950	$1.1B	2026-06-30
MASSACHUSETTS FINANCIAL SERVICES	3,801,077	$850.4M	2026-06-30
MORGAN STANLEY	3,950,067	$831.8M	2026-06-30
WELLINGTON MANAGEMENT GROUP LLP	3,502,897	$737.6M	2026-06-30
Orbis Allan Gray Ltd	2,677,710	$563.8M	2026-06-30
GEODE CAPITAL MANAGEMENT	2,615,842	$548.6M	2026-06-30
GENERATION INVESTMENT MANAGEMENT LLP	2,280,698	$480.2M	2026-06-30

SEC EDGAR: CIK 1757898 →

STERIS plc

STE

NYSELarge CapHealthcare

InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro Quality Score

68.2/100

Rank #326 of 2,961 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Price Chart

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

What's Driving STE's Business? Latest 10-Q Breakdown

AI-extracted from the 10-Q filed 2026-08-07 — Q1 FY2027 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Biggest Revenue Drivers

Healthcare segment$1,048.3M+7.6% YoY

Growth in service (+9.6%), consumable (+9.2%), and capital equipment (+1.4%) driven by increased volume and pricing.

Applied Sterilization Technologies (AST)$297.6M+5.8% YoY

Constant currency organic growth of 4.7% primarily from increased pricing, partially offset by volume decline.

Biggest Revenue Drivers

Total revenue: $1,492.7M+7.3% YoY

Healthcare segment$1,048.3M+7.6% YoY

Growth in service (+9.6%), consumable (+9.2%), and capital equipment (+1.4%) driven by increased volume and pricing.

Applied Sterilization Technologies (AST)$297.6M+5.8% YoY

Constant currency organic growth of 4.7% primarily from increased pricing, partially offset by volume decline.

Life Sciences segment$146.7M+8.6% YoY

Growth in capital equipment (+17.4%), consumable (+8.2%), and service (+2.4%) driven by increased volume and pricing.

Largest Expense Items

Cost of revenues$808.6M+5.9% YoY

Increase driven by higher volume and inflation, partially offset by favorable pricing and productivity.

Selling, general, and administrative$369.7M+4.5% YoY

Increase attributable to higher compensation and benefit costs and marketing/sales spending, offset by favorable FX and lower bad debt.

Research and development$28.6M+8.5% YoY

Continued investment focused on sterile processing, procedural products, and gastrointestinal endoscopy device capabilities.

Margins: Gross profit margin expanded 70 basis points to 45.8%, driven by favorable pricing (100 bps), productivity (40 bps), and mix (40 bps), partially offset by inflation (60 bps) and adjustments (50 bps). Operating margin improved on higher volumes and operational efficiency.

Watch Items from the Filing

New restructuring plan announced post-quarter (Aug 5, 2026) expects $55M–$70M in total charges, with completion targeted in FY2030, impacting Chemistry manufacturing consolidation.
IRS dispute regarding deemed dividend inclusions and withholding tax for FY2018; potential liability of $50M (excluding interest/penalties); case pending in U.S. Tax Court.
Illinois EO litigation settlement obligations of $48.2M accrued in FY2025; substantially all payments made by July 31, 2026, with claims administration largely completed.
AST segment operating margin declined 60 bps to 48.0% due to higher depreciation, lower productivity, and labor inflation outweighing pricing gains.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →